London
· Delayed Price · Currency is GBP · Price in USD CRISPR Therapeutics AG Company Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA.
The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.
It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
| Country | Switzerland |
| Founded | 2013 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 407 |
| CEO | Samarth Kulkarni |
Contact Details
Address: Baarerstrasse 14 Zug, 6300 Switzerland | |
| Phone | 41 41 561 32 77 |
| Website | crisprtx.com |
Stock Details
| Ticker Symbol | 0VRQ |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Samarth Kulkarni | Chief Executive Officer |
| Raju Prasad | Chief Financial Officer |
| Julianne Bruno | Chief Operating Officer |
| Susan Kim | Head of Investor Relations |